Mylan's 2nd-qtr earnings plunge on higher costs and product approval delays

7 August 2014

US generics major Mylan (Nasdaq: MYL) has reported that profits dropped nearly 30% in the second quarter of 2014, despite higher revenue, as expenses rose and there were delays in US Food and Drug Administration approvals.

The company earned $125.2 million, or $0.32 per share, down from $177.7 million, or $0.46 in the like 2013 quarter in the same period last year. Revenue increased 8% to $1.84 billion. Adjusted diluted earnings per share (EPS) were $0.69, an increase of 1% and in line with company guidance; generally accepted accounting principles (GAAP) diluted EPS of $0.32.

Generics segment third party sales were $1.53 billion, up 6% on a constant currency basis. Specialty segment third party sales were $287.8 million, up 22%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK